List of Figures:
Figure 2-1: Nominal GDP (Billion US$), 2008-2010
Figure 2-2: Consumer Price Index (%), 2010-2014
Figure 2-3: Population (Million), 2010-2014
Figure 2-4: Life Expectancy (Years), 2010-2014
Figure 2-5: Population Breakup by Age Group (%), 2010-2014
Figure 2-6: Per Head Healthcare Spending (US$), 2010-2014
Figure 2-7: Number of Doctors (2010-2014)
Figure 2-8: Number of Hospital Beds (per ‘000 Population), 2010-2014
Figure 4-1: Pharmaceutical Sales (Billion CAD), 2010-2014
Figure 4-2: Prescriptions Dispensed in Branded Drugs Market (Million), 2006-2010
Figure 4-3: Prescriptions Dispensed in Generic Drugs Market (Million), 2006-2010
Figure 4-4: Share of Generic and Branded Drugs by Prescription (2006-2010)
Figure 4-5: Average Retail Price of Generic and Branded Drugs (CAD), 2006-2010
Figure 4-6: Generic Drug Sales (Billion CAD), 2010-2014
Figure 4-7: Branded Drug Sales (Billion CAD), 2010-2014
Figure 4-8: Share of Generic and Branded Drugs by Sales (2010-2014)
Figure 4-9: Branded Drug Sales through Retail Pharmacies (Billion CAD), 2010-2014
Figure 4-10: Generic Drug Sales through Retail Pharmacies (Billion CAD), 2010-2014
Figure 4-11: Share of Generic and Branded Drug Sales through Retail Pharmacies (2010-2014)
Figure 4-12: Branded Drug Sales through Hospital Pharmacies (Billion CAD), 2010-2014
Figure 4-13: Generic Drug Sales through Hospital Pharmacies (Billion CAD), 2010-2014
Figure 4-14: Share of Generic and Branded Drug Sales through Hospital Pharmacies (2010-2014)
Figure 4-15: Share of Independent Generic and Authorized Generic Prescriptions (2005-2008)
Figure 4-16: Generic Drugs Market by Retail and Hospital Sales (%), 2010
Figure 4-17: Cardiovascular Drug Market (Billion CAD), 2010-2014
Figure 4-18: Psychotherapeutics Market (Billion CAD), 2010-2014
Figure 4-19: Cholesterol Agents Market (Billion CAD), 2010-2014
Figure 4-20 Neurological Agents Market (Billion CAD), 2010-2014
Figure 4-21: Number of Diabetes Patients in Age Group 20-79 Years (Million), 2010 & 2030
Figure 4-22: Diabetes Therapy Market (Million CAD), 2010-2014
List of Tables:
Table 3-1: Patent Expiration for Some Hypertension Drugs (2012)
Table 3-2: Patent Expiration of Key Drugs (2012)
Table 4-1: Top Ten Therapy Areas by Prescription (‘000), 2010
Table 4-2: Per Capita Drug Spending of Public and Private Sector by Region (CAD), 2010
Table 4-3: Generic Drug Prescriptions Dispensed by Region (%), 2006-2010
Table 4-4: Generic Drug Sales by Region (%), 2006 & 2010
Table 4-5 Top Ten Therapy Areas by Retail Pharmacy Sales (Billion CAD), 2010
Table 4-6: Number of Retail Pharmacies by Category (2006-2011)
Table 4-7: Top Ten Therapy Areas by Hospital Sales (Million CAD), 2010
Table 6-1: Top Pharmaceutical Companies by Sales (Billion CAD), 2010
Table 6-2: Top Generic Drug Companies by Prescription (Million), 2007
Table 6-3: Top Generic Drug Companies by Sales (Million CAD), 2007
Table 6-4: Apotex - Strengths & Weaknesses
Table 6-5: Teva Canada Ltd. (Novopharm) - Strengths & Weaknesses
Table 6-6: Mylan - Strengths & Weaknesses
